Full Press Release Details
Editor’s note (June 5): This story has been removed from theBioSpacewebsite because it was errantly posted without editorial review.
RCUS Negative Sentiment
ASCO: Gilead and Arcus’s Cancer Immunotherapy Combo Faces Scrutiny Over Lower Survival Rates
Key Takeaway: The article highlights concerns regarding a cancer immunotherapy combination from Gilead and Arcus, particularly focusing on lower survival rates. This news has sparked scrutiny within the medical community. Additionally, the article was removed from the BioSpace website due to a lack of editorial review before publication.
Price reaction · baseline $21.01 (2023-06-02 close) · hit after-hours · clean, no other RCUS news in the window
day 0 close
-2.2%
day 1
-4%
day 3
+3%
Market Sentiment Analysis
CONCERNS & RISKS
- The article discusses lower survival rates for a cancer immunotherapy combo.
- There is scrutiny over the effectiveness of the treatment.
- The news was published without proper editorial review.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~19 mo
Low dilution risk
Lead asset
Atezolizumab
Phase 2 · Prostate Adenocarcinoma
Frequently Asked Questions
What is the main concern about the Gilead and Arcus combo?
The main concern is the lower survival rates associated with the cancer immunotherapy combination.
Why was the article removed from BioSpace?
The article was removed because it was posted without proper editorial review.
What does the scrutiny involve?
The scrutiny involves questioning the effectiveness of the cancer immunotherapy treatment.